Your session is about to expire
← Back to Search
Tranexamic Acid for Subdural Hematoma (TRACE-2 Trial)
TRACE-2 Trial Summary
This trial is testing whether the drug Tranexamic acid can reduce the volume of chronic subdural hematomas, which are collections of blood in the space between the brain and the skull that can cause severe neurological problems. The trial is designed as a double-blinded randomized controlled trial, which means that half of the patients will be given the drug and half will be given a placebo, and neither the patients nor the doctors will know who is receiving which. The primary endpoint is the change in volume of the hematoma after 4-8 weeks of treatment, and secondary endpoints include the hematoma volume at 8-12 weeks
- Subdural Hematoma
TRACE-2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTRACE-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TRACE-2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Placebo Control Arm
- Group 2: Tranexamic Acid Arm
Frequently Asked Questions
What medical indications warrant the consumption of Tranexamic Acid 500 MG?
"Tranexamic Acid 500 MG is utilized to reduce the destruction of fibrin, and can also be prescribed for hemophilia, dental extractions, or other forms of bleeding."
Has the FDA granted approval for Tranexamic Acid 500 MG?
"The safety score of Tranexamic Acid 500 MG was assessed as a 2, since there is some evidence validating its security but no proof demonstrating efficacy."
Are there any participants needed for this research endeavor?
"As documented on clinicaltrials.gov, the original posting of this trial was recorded as July 1st 2021 and has not been recently updated since May 18th 2021; thus, it is presently not looking for participants. However, there are 120 other studies that have open recruitment positions available at present."
How many individuals are being selected to participate in this research endeavor?
"The search for participants in this particular trial has concluded, as the last edit to its profile was made on May 18th 2021. If you are seeking out alternative trials, there are currently 59 clinical studies recruiting patients with hematoma and subdural issues and 61 related to Tranexamic Acid 500 MG."
Have there been any prior tests of Tranexamic Acid 500 MG's efficacy?
"Presently, there are a total of 61 active clinical trials dealing with the effects and efficacy of Tranexamic Acid 500 MG. Among these clinical studies, 26 have made it to Phase 3. While most research is conducted in Kansas City, Kansas; other 185 sites across different countries are also collecting data for this medication's usage."
Share this study with friends
Copy Link
Messenger